secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-01-30T23:59:59+00:00
Accession:  0001193125-23-018358
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave closes $50M equity sale to GSK affiliate; collaboration effective, triggering $120M upfront
--------------------------------------------------------------------------------

- Closed sale of 10,683,761 ordinary shares to Glaxo Group Limited for $50M cash.
- Collaboration and License Agreement with GSK effective January 27, 2023.
- GSK must now pay $120M upfront cash plus first research support funding.
- Investor Agreement with GGL entered into as previously disclosed on Dec 13, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523018358/0001193125-23-018358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523018358/d451816d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-018358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer